HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
fananserin
RN & structure given in first source
Also Known As:
2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; RP 62203; RP-62203; fananserine
Networked:
4
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Naphthalenes: 18
fananserin: 4
Sulfur Compounds: 278
Cyclic S-Oxides
fananserin: 4
Heterocyclic Compounds: 198
Heterocyclic Oxides
Cyclic S-Oxides
fananserin: 4
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Naphthalenes: 18
fananserin: 4
Experts
1.
Semba, Jun'ichi
: 1 article (02/2004)
Related Diseases
1.
Schizophrenia (Dementia Praecox)
03/01/1999 - "
The authors' objective was to assess the potential efficacy of fananserin (RP62203), a potent antagonist at the D4 and serotonin2A (5-HT2A) receptors, on symptoms of schizophrenia.
"
02/01/2004 - "
Two D4 antagonists (L-745,879 and fananserine) failed to show clinical efficacy in schizophrenia.
"
03/01/1999 - "
Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.
"
2.
Psychomotor Agitation (Akathisia)
03/01/1999 - "
The patients' extrapyramidal symptoms did not worsen during the trial, but the patients given fananserin had an increase in akathisia.
"
3.
Sleep Wake Disorders
04/01/1992 - "
RP 62203 could therefore be of clinical interest in the management of sleep disorders, particularly those developing within a psychiatric context.
"
4.
Catalepsy
02/19/1998 - "
WAY-100635 (0.1-3 mg/kg, s.c.), ketanserin (0.1-3 mg/kg, s.c.), MDL 100,151 (0.3-3 mg/kg, s.c.) and fananserin (RP 62203; 3 mg/kg, s.c.) induced a significant catalepsy.
"
Related Drugs and Biologics
1.
Serotonin 5-HT2 Receptor Antagonists
2.
fananserin
3.
Ketanserin
4.
MDL 100,151
5.
N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamide